5 unchanged sentences
Method of Filing
−Removed: Certificate of Amendment to the Certificate of Incorporation, as amended, of Diffusion Pharmaceuticals Inc.
−Removed: Incorporated by reference to Exhibit 3.1 to the registrant's current report on Form 8-K filed on April 18, 2022
−Removed: Amendment to the Bylaws, as amended, of Diffusion Pharmaceuticals Inc., effective March 18, 2022
−Removed: Incorporated by reference to Exhibit 3.2 to the registrant's current report on Form 8-K filed on March 18, 2022
−Removed: Certificate of Designation of Preferences, Rights, and Limitations of Series C Convertible Preferred Stock
−Removed: Incorporated by reference to Exhibit 3.1 to the registrant's current report on Form 8-K filed on March 18, 2022
−Removed: Form of Subscription Agreement between Diffusion Pharmaceuticals Inc.
−Removed: and the investors named therein, dated March 18, 2022
−Removed: Incorporated by reference to Exhibit 10.1 to the registrant's current report on Form 8-K filed on March 18, 2022
+Added: Employment Agreement, effective May 18, 2022, by and between the Company and Raven Jaeger, M.S.
+Added: Incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed June 28, 2022
Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 and SEC Rule 13a-14(a)
8 unchanged sentences
Furnished herewith
−Removed: The following materials from Diffusion’s quarterly report on Form 10-Q for the quarter ended March 31, 2022, formatted in Inline XBRL (Extensible Business Reporting Language):
−Removed: (i) the Unaudited Consolidated Balance Sheets, (ii) the Unaudited Consolidated Statements of Operations, (iii) the Unaudited Consolidated Statement of Changes in Stockholders’ Equity, (iv) the Unaudited Consolidated Statements of Cash Flows, and (v) Notes to Unaudited Consolidated Financial Statements
+Added: The following materials from Diffusion’s quarterly report on Form 10-Q for the quarter ended June 30, 2022 formatted in inline XBRL (Extensible Business Reporting Language):
+Added: (i) the Unaudited Consolidated Balance Sheets, (ii) the Unaudited Consolidated Statements of Operations, (iii) the Unaudited Consolidated Statement of Changes in Stockholders’ Equity (Deficit), (iv) the Unaudited Consolidated Statements of Cash Flows, and (v) Notes to Unaudited Consolidated Financial Statements
Filed herewith
1 unchanged sentence
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
+Added: August 11, 2022
DIFFUSION PHARMACEUTICALS INC.
/s/ Robert J.
−Removed: Cobuzzi, Jr., Ph.D.
−Removed: Cobuzzi, Jr., Ph.D.
President and Chief Executive Officer
3 unchanged sentences
Chief Financial Officer
−Removed: (Principal Financial and Accounting Officer)
+Added: (Principal Financial Officer and Principal Accounting Officer)
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.